- Home
- DPRO vs HOOK Comparison
DPRO vs HOOK Comparison
Compare DPRO & HOOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DPRO
- HOOK
- Stock Information
- Founded
- DPRO 1998
- HOOK 2011
- Country
- DPRO Canada
- HOOK United States
- Employees
- DPRO N/A
- HOOK N/A
- Industry
- DPRO Aerospace
- HOOK Biotechnology: Pharmaceutical Preparations
- Sector
- DPRO Industrials
- HOOK Health Care
- Exchange
- DPRO Nasdaq
- HOOK Nasdaq
- Market Cap
- DPRO 10.4M
- HOOK 9.3M
- IPO Year
- DPRO N/A
- HOOK 2019
- Fundamental
- Price
- DPRO $3.04
- HOOK $1.25
- Analyst Decision
- DPRO Strong Buy
- HOOK Buy
- Analyst Count
- DPRO 2
- HOOK 4
- Target Price
- DPRO $5.25
- HOOK $10.67
- AVG Volume (30 Days)
- DPRO 2.5M
- HOOK 60.9K
- Earning Date
- DPRO 08-12-2025
- HOOK 08-07-2025
- Dividend Yield
- DPRO N/A
- HOOK N/A
- EPS Growth
- DPRO N/A
- HOOK N/A
- EPS
- DPRO N/A
- HOOK N/A
- Revenue
- DPRO $4,716,450.00
- HOOK $9,351,000.00
- Revenue This Year
- DPRO $94.01
- HOOK N/A
- Revenue Next Year
- DPRO $95.14
- HOOK N/A
- P/E Ratio
- DPRO N/A
- HOOK N/A
- Revenue Growth
- DPRO 7.90
- HOOK N/A
- 52 Week Low
- DPRO $1.55
- HOOK $0.72
- 52 Week High
- DPRO $6.09
- HOOK $6.77
- Technical
- Relative Strength Index (RSI)
- DPRO 57.61
- HOOK 38.94
- Support Level
- DPRO $2.46
- HOOK $1.23
- Resistance Level
- DPRO $3.22
- HOOK $1.30
- Average True Range (ATR)
- DPRO 0.38
- HOOK 0.06
- MACD
- DPRO 0.03
- HOOK -0.03
- Stochastic Oscillator
- DPRO 35.81
- HOOK 5.97
About DPRO Draganfly Inc.
Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The three segments are Drones, Vital (Vital Intelligence), and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Vital segment derives its revenue from the sale of products that measure vitals to help detect symptoms from large groups of people from a distance. The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.